title: Effects of KST48 [(2R,5SR)3-(2-chlorobenzoyl)-5-(4-chlorophenoxymethyl)-2(3,4-dichlorophenyl) oxazolidine] on glucose transport in L6 myocytes.
abstract: KST48 [(2R,5SR)3-(2-chlorobenzoyl)-5-(4-chlorophenoxymethyl)-2-(3,4-dichlorophenyl)oxazolidine] is an oxazolidine derivative that showed significant stimulating effects on glucose transport in L6 myocytes. The effects of KST48 on glucose uptake were assayed by measuring the transport of 2-deoxyglucose in L6 myocytes. The translocation of glucose transport-4 (GLUT-4) was examined by western blot analysis. KST48 enhanced glucose transport in a concentration dependent manner and the maximum effect was observed at 50 micromol/L. The stimulation of glucose transport was characterized as the increase in Vmax without any significant change of Km value. This enhanced glucose transport was found to be decreased by the treatment with phenylarsine oxide and genistein, but not by the treatment with wortmannin and tyrphostin 25. KST48 was also proved to increase the GLUT-4 translocation. These results suggest that KST48 increases glucose transport in L6 myocytes by stimulating the translocation of GLUT4 to plasma membrane and this action might be mediated by protein tyrosine kinase but not by phosphatidyl inositol 3-kinase.
authors.affiliation: College of Pharmacy, Seoul National Universitya, Seoul, Korea.
authors.forename: Dong-Ook
authors.initials: DO
authors.lastname: Lee
authors.forename: Lee-Yong
authors.initials: LY
authors.lastname: Khil
authors.forename: Tong-Shin
authors.initials: TS
authors.lastname: Chang
authors.forename: Ho-Kyu
authors.initials: HK
authors.lastname: Han
authors.forename: Sang-Ho
authors.initials: SH
authors.lastname: Chae
authors.forename: Mee-Young
authors.initials: MY
authors.lastname: Ahn
authors.forename: You-Mie
authors.initials: YM
authors.lastname: Lee
authors.forename: Byung-Hoon
authors.initials: BH
authors.lastname: Lee
authors.forename: jin-Ho
authors.initials: jH
authors.lastname: Jung
authors.forename: Young-Chul
authors.initials: YC
authors.lastname: Kim
authors.forename: Chang-Kiu
authors.initials: CK
authors.lastname: Moon
mesh_terms: D000963:Antimetabolites / Q000378:metabolism; D002460:Cell Line; D002470:Cell Survival; D003847:Deoxyglucose / Q000378:metabolism; D004591:Electrophoresis, Polyacrylamide Gel; D005947:Glucose / Q000378:metabolism*; D051275:Glucose Transporter Type 4; D006843:Hydrocarbons, Chlorinated / Q000494:pharmacology*; D007004:Hypoglycemic Agents / Q000494:pharmacology; D015151:Immunoblotting; D007328:Insulin / Q000494:pharmacology; D007700:Kinetics; D008687:Metformin / Q000494:pharmacology; D009004:Monosaccharide Transport Proteins / Q000378:metabolism; D032342:Muscle Cells / Q000187:drug effects / Q000378:metabolism*; D009124:Muscle Proteins / Q000378:metabolism; D032446:Myoblasts / Q000187:drug effects / Q000378:metabolism; D010080:Oxazoles / Q000494:pharmacology*; D021381:Protein Transport / Q000187:drug effects; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D013347:Subcellular Fractions / Q000187:drug effects / Q000378:metabolism
chemical_list: C496268:(2R,5SR)3-(2-chlorobenzoyl)-5-(4-chlorophenoxymethyl)-2(3,4-dichlorophenyl) oxazolidine; D000963:Antimetabolites; D051275:Glucose Transporter Type 4; D006843:Hydrocarbons, Chlorinated; D007004:Hypoglycemic Agents; D007328:Insulin; D009004:Monosaccharide Transport Proteins; D009124:Muscle Proteins; D010080:Oxazoles; D008687:Metformin; D003847:Deoxyglucose; D011505:Protein-Tyrosine Kinases; D005947:Glucose